FDA advisers recommend approval of Alzheimer's drug lecanemab.
TL;DR Summary
A panel of FDA advisers has recommended full regulatory approval for lecanemab, a new drug that can slow cognitive decline in Alzheimer's patients. The drug can remove sticky amyloid plaques from the brain and has been shown to slow cognitive decline by 27% in people with mild cognitive impairment or mild Alzheimer's dementia. However, the drug has some serious side-effects, including brain swelling and bleeding or microhemorrhages. Full FDA approval would make lecanemab the first drug to modify the course of the disease, not simply treat its symptoms.
- FDA advisers say new Alzheimer’s drug lecanemab slows cognitive decline The Guardian US
- FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment CNN
- Alzheimer's drug gets FDA panel's backing, paving way for full approval 11Alive
- FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer CNBC
- Biogen Stock in Focus on Key Vote on Lequembi TipRanks
Reading Insights
Total Reads
0
Unique Readers
14
Time Saved
1 min
vs 2 min read
Condensed
76%
367 → 88 words
Want the full story? Read the original article
Read on The Guardian US